Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionDanske Bank A/s
Latest Disclosed Ownership65,955 shares
Latest Disclosed Value $ 21,822,531
Danske Bank A/s reports 1.85% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Danske Bank A/s filed a 13F-HR form disclosing ownership of 65,955 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $18,843,344 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 67,201 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -1.85% during the quarter. The current value of the position is $17,181,278 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 65,955 -1,246 -1.85 21,823 -18.34 0.0247
2026-02-02 2025-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 67,201 9,794 17.06 26,722 2.08 0.0621
2025-11-19 2025-09-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 57,407 2,400 4.36 26,178 45.94 0.0651
2025-12-18 2025-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 55,007 1,802 3.39 17,937 24.86 0.0445
2025-12-18 2025-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 53,205 -8,808 -14.20 14,366 -1.55 0.0439
2026-03-18 2024-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 62,013 9,608 18.33 14,592 1.25 0.0436
2026-03-18 2024-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 52,405 100 0.19 14,413 13.39 0.0480
2026-03-18 2024-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 52,305 -17,186 -24.73 12,710 22.39 0.0469
2026-03-18 2024-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 69,491 69,491 10,385 0.0326
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.